RxDoctor Payments Data

John Shoup, MD

Internal Medicine · Wentzville, MONPI 1427476100

Payments from drug & device makers

$843in general payments, 2019–2025

Across 50 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$156
  • Pfizer$110
  • AbbVie$99
  • Kestra Medical Technology Services, Inc.$73
  • Lilly USA, LLC$70
  • GSK$68
  • plus $267 from 9 others

What the payments were for

  • Food & beverage$843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$843 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$124,231
Medicare patients
313
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$192,839
EliquisApixaban152$170,969
JardianceEmpagliflozin56$87,050
TrulicityDulaglutide35$55,029
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$38,924
XareltoRivaroxaban24$32,260
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$31,496
MounjaroTirzepatide27$28,686
MyrbetriqMirabegron26$27,021
FarxigaDapagliflozin Propanediol21$18,544
Incruse ElliptaUmeclidinium Bromide13$12,145
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,607
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl24$7,594
ArexvyRsvpref3 Antigen/As01e/Pf29$7,069
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$6,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$156$192,839126 claims
PfizerEliquis, Abrysvo$110$176,428172 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arexvy, Breo Ellipta$68$94,445141 claims
Lilly USA, LLCTrulicity, Mounjaro$70$83,71562 claims
Johnson & JohnsonXarelto$39$32,26024 claims
AstraZenecaFarxiga, Breztri Aerosphere$45$26,15133 claims
AbbVieCreon$99$3,16614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Wentzville

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →